No Data
No Data
No Data
Anke Biotech (300009.SZ): The clinical trial of AFN0328 injection with a new indication was accepted
On May 14, Ge Longhui (300009.SZ) announced that the clinical trial application for new indications of the “AFN0328 injection” jointly declared by the company and participating companies Hefei Afana Biotechnology Co., Ltd. has been accepted, and an administrative licensing document “Notice of Acceptance” has been obtained from the State Drug Administration. The acceptance number is: CXSL2400288. AFN0328 injection is an mRNA drug for cancer treatment, which was jointly developed by the company and Afana.
Anke Biotech (300009.SZ): Using genetic recombination technology, it has developed various drugs such as human growth hormone injections, human interferon injections, and trastuzumab for injections
Gelonghui, May 8, 丨 Anke Biology (300009.SZ) said on the investor interactive platform that synthetic biology comprehensive genetic engineering, bioengineering, chemical synthesis and computer simulation technologies can be applied to various fields such as medicine, chemicals, agriculture, environment, etc. Our company has been deeply involved in the biopharmaceutical field for many years, and has used genetic recombination technology to develop various drugs such as human growth hormone injections, human interferon injections, and trastuzumab for injections, and actively use computer simulation and other technologies to assist in the development of new products. and the layout of the new pipeline.
Anke Biotech (300009.SZ): Currently, the company also has a layout in cutting-edge technologies such as cell therapy, mRNA drugs, and oncolytic viruses
Gelonghui, May 8, 丨 Anke Biotech (300009.SZ) said on the investor interactive platform that our company's main business is biopharmaceutical R&D, production and sales, and also lays out fields such as diagnostic reagents, genetic testing, functional skincare products, etc., and has already launched related products. Currently, the company also has a layout in cutting-edge technologies such as cell therapy, mRNA drugs, and oncolytic viruses.
Anke Biotech (300009.SZ): The company's 2023 growth hormone sales revenue is close to 70% of consolidated revenue
Gelonghui, May 8, 丨 Anke Biotech (300009.SZ) said on the investor interactive platform that the company's 2023 growth hormone sales revenue was close to 70% of consolidated revenue, and the parent company achieved net profit of 763 million, mainly contributing to growth hormone.
As Anhui Anke Biotechnology (Group) (SZSE:300009) Soars 10% This Past Week, Investors May Now Be Noticing the Company's Three-year Earnings Growth
While it may not be enough for some shareholders, we think it is good to see the Anhui Anke Biotechnology (Group) Co., Ltd. (SZSE:300009) share price up 24% in a single quarter. But that doesn't he
Anke Biotech (300009.SZ): AFN0328 injection was accepted for drug registration
Anke Biotech (300009.SZ) announced that the company and participating company Hefei Afana Biotechnology Co., Ltd. (abbreviation...
No Data